Sweden’s most promising startups
Sting has contributed to the development of over 200 companies, primarily in ICT, Internet/media, cleantech, sustainability, health and life science. We offer two programmes: Sting Accelerate and Sting Incubate. Here you can read about the companies who are currently a part of Sting and also get to know some more about our alumni companies.
iCellate sets a new standard for marker-independent processing technology for cell samples for medical diagnosis as well as basic and clinical research. The technique provides better quality of the sample by removing unwanted cells and other impurities naturally, while optimizing the density of cells of interest for downstream applications, whether for establishing cancer diagnosis, innovative cancer research or developing new and revolutionary health products. The technology supports a safer and more effective diagnosis of cancer today and enables a paradigm shift in health care tomorrow.